Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IAE 0972

Next Previous
X
Search
Drug Profile

IAE 0972

Alternative Names: IAE-0972

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SUNHO (China) BioPharmaceutical
  • Class Antineoplastics; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists; Interleukin 10 stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 05 Dec 2024 SUNHOChinaBioPharmaceutical plans a phase II/III trial for Squamous cell cancer and Nasopharyngeal cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Recurrent, Combination therapy) in January 2025 (IV) (NCT06719479)
  • 21 Jul 2023 Preliminary safety and efficacy data from a phase I trial in Solid Tumors released by SunHo BioPharmaceuticals
  • 21 Jul 2023 SunHo BioPharamaceuticals plans a phase II trial for solid tumors (Late-stage disease, Metastatic disease) in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top